• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biotrial contests Marisol Touraine’s statement, disagrees with IGAS

Biotrial contests Marisol Touraine’s statement, disagrees with IGAS

May 26, 2016
CenterWatch Staff

Biotrial, a medical research center in Rennes, France, has released a statement expressing shock over Health Minister Marisol Touraine’s statements regarding a recent trial that caused the death of a patient.

Biotrial received the General Inspectorate of Social Affairs’ (IGAS) final report at the same time the press conference—which Biotrial was not invited to attend—was ending. This report had, however, been previously provided to the media on Sunday evening.

Regarding the plan of action required by the Social Affairs and Health Minister, Biotrial had already begun to put one into place following exchanges with the French National Agency for the Safety of Medicines and Health Products (ANSM). In addition, the ANSM and the Regional Health Agency’s (ARS) recommendations were immediately put into place after the accident in January 2016.

According to Biotrial, the clinical research center did not wait for the IGAS report and the Health Minister recommendations to make volunteer care improvement its utmost priority.

Regarding the General Inspectorate of Social Affairs’ report, Biotrial contests the conclusions from the IGAS final report which, in order to stay consistent with the report that was hastily published in February, would not allow itself to include the input provided by Biotrial. The center deplores the methods, which it considers contrary to legal procedures that were used to put together the report. Biotech believes this has “remove[d] all of its credibility.”

Biotrial will submit to the Health and Social Affairs Minister its plan of action, which is already in place.

Biotrial stated the Portuguese Laboratory Bial’s compound, by it unexpected and unpredictable toxicity, was at fault for the accident.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing